Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

Pfizer

Status and phase: Completed; Phase 2

Conditions: Reduction of Hypertrophic Skin Scarring

Treatments: Drug: PF-06473871

Study type: Interventional

Funder types: Industry

Identifiers

NCT01730339

B5301001

2012-004355-37 (EudraCT Number)

Details and patient eligibility

About

The study will compare how well PF-06473871 works versus placebo in reducing skin scarring after scar revision surgery of existing breast scars. The study will also evaluate the safety of PF-06473871 in healthy adult subjects.

Enrollment: 103 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects must have hypertrophic (raised) breast scars from previous surgery
• Subjects must be healthy

Exclusion criteria

• Currently pregnant or pregnant during the 6 months, prior to inclusion in the study or breast-feeding.
• Presence of history of breast cancer

Trial design

103 participants in 2 patient groups

Group 1

Active Comparator group

Treatment:

Drug: PF-06473871

Drug: PF-06473871

Group 2

Active Comparator group

Treatment:

Drug: PF-06473871

Drug: PF-06473871